Journal of Isfahan Medical School

Journal of Isfahan Medical School

Acquired Mutation of the Tyrosine Kinase JAK2 V617F in the ABL-BCR-Negative Chronic Myeloproliferative Diseases in a Population of West Azerbaijan Province, Iran

Document Type : Original Article (s)

Authors
Morteza Bagheri 1
Isa Abdi-Rad 2
Davood Malek 3
Ali Eishi 3
Nasim Valizadeh 3
1 Assistant Professor, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
2 Professor, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
3 Hematooncologist, Department of Hematology and Oncology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
10.22122/jims.v35i459.9227
Abstract
Background: JAK2 V617F mutation presents in the majority of the ABL-BCR-negative chronic myeloproliferative disorders, nearly all the patients with polycythemia vera, about 50% of cases with essential thrombocytosis, or primary myelofibrosis, and 20% of patients with Philadelphia negative chronic myeloid leukemia. This mutation is an acquired and somatic point mutation and results in cytokine signaling as well as clonal hematopoiesis activation. This study was carried out to evaluate the JAK2 V617F mutation in patients with the ABL-BCR-negative chronic myeloproliferative disorders in the west Azerbaijan Province, Iran.Methods: 43 patients with the ABL-BCR-negative chronic myeloproliferative diseases entered the study. Peripheral blood samples were obtained for total DNAs and RNAs extraction via standard methods. The JAK2 V617F mutation was tested using amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) and allele-specific oligonucleotide-real time-polymerase chain reaction (ASO-RT-PCR) methods.Findings: The frequency of JAK2 V617F mutation was 76.74% (33/43) in our samples using both methods.Conclusion: Our results indicate that JAK2 V617F mutation is more frequent among patients with the ABL-BCR-negative chronic myeloproliferative diseases in Iranian west Azerbaijani patients. ARMS-PCR and ASO-RT-PCR methods are fast and inexpensive methods to recognize the JAK2 V617F mutation which is useful for management of patients with ABL-BCR-negative chronic myeloproliferative diseases.
Keywords
Myeloproliferative disorders
JAK2 protein tyrosine kinase
Mutation
  1. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11(12): 546-54.
  2. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: It all makes sense. Blood 2005; 105(11): 4187-90.
  3. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007; 31(8): 1053-62.
  4. Reuther GW. JAK2 activation in myeloproliferative neoplasms: A potential role for heterodimeric receptors. Cell Cycle 2008; 7(6): 714-9.
  5. Neet K, Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996; 1(2): 147-69.
  6. Orr DW, Patel RK, Lea NC, Westbrook RH, O'Grady JG, Heaton ND, et al. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010; 31(12): 1330-6.
  7. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108(6): 1865-7.
  8. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18.
  9. Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res 2010; 132: 423-7.
  10. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009; 22(3): 476-87.
  11. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372(9648): 1484-92.
  12. Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol 2014; 93(5): 791-6.
  13. Bennett M, Stroncek DF. Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med 2006; 4: 41.
  14. Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005; 128(5): 583-92.
  15. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991; 66(3): 287-99.
  16. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22(1): 14-22.
  17. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106(8): 2920-1.
  18. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. Br J Haematol 2005; 130(6): 964-5.
  19. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017; 129(6): 667-79.
  20. Karimzadeh P, Ghaffari SH, Ferdowsi S, Chahardouli B, Saltanatpouri Z, Einollahi N, et al. Comparisions of ARMS-PCR and AS-PCR for the evaluation of JAK2V617F mutation in patients with non-CML myeloproliferative neoplasms. Int J Hematol Oncol Stem Cell Res 2010; 4(2): 10-3.
  21. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med 2008; 11(3): 247-51.
  22. Poopak B, Mirmongereh H, Pourfathollah A, Sharifian R, Rezvani H, Elahi F, et al . Evaluation of JAK2 V617F mutation in Iranian patients with non-CML myeloproliferative neoplasms. Sci J Iran Blood Transfus Organ. 2009; 5(4): 237-45. [In Persian].
  23. Poopak B, Farshdousti Hagh M, Saki N, Elahi F, Rezvani H, Khosravipour G, et al. JAK2 V617F mutation in Iranian patients with myeloproliferative neoplasms: Clinical and laboratory findings. Turk J Med Sci 2013; 43: 347-53.
  24. Asghari A, Shahriari Ahmadi A, Basi A, Vkili M, Razavi M, Arabi M, et al. The Association between prevalence of JAK2V617F mutation and blood indicies in groups of patients with myeloproliferative neoplasms in Rasul Akram Hospital. Int J Hematol Oncol Stem Cell Res 2011; 5(4): 10-3.
  25. Ghotaslou A, Nadali F, Chahardouli B, Ghasemi A, Abbasian S, Ghaffari K, et al. Frequency of c-MPL and JAK2V617F Mutations in Iranian Patients with Philadelphia-Negative Myeloproliferative Disorders and its Association with Clinical and Laboratory Findings. J Isfahan Med Sch 2014; 32(301): 1487-95. [In Persian].
  26. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366(9501): 1945-53.
  27. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20(1): 168-71.
  28. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 2007; 127(5): 736-43.
  29. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44(6): 1528-34.
  30. Colaizzo D, Amitrano L, Iannaccone L, Vergura P, Cappucci F, Grandone E, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44(6): 412-6.
Journal of Isfahan Medical School
Volume 35, Issue 459 - Serial Number 459
November and December 2018
Pages 1785-1791

  • Receive Date 22 November 2017
  • Accept Date 06 April 2022